Utilizing genetically engineered mouse models of tumor specific manifestations of both NF1 and NF2, and appropriate cell lines, the preclinical consortium has focused on screening and testing potential therapeutic options of reach tumor type. This evidence concerns the gene NF2 and neoplasm.